Cancer was found in 9.6% of MSA+ve patients. The most frequent tumors were gynecological (37.5%), followed by gastrointestinal (25%) and breast cancer (12.5%). Factors associated with cancer were age (p=0.01), TIF1γ (p=0.001), SRP (p=0.004), PL-7 (p=0.013), PL-12 (p=0.047) and HMGCR (p=0.027).

The mortality of these patients was 3.5%. There were no differences regarding MSA+ve vs MSA-ve (p = 0.911). However, MDA-5 (p=0.033) and older age (p=0.001) were associated with higher mortality. There were no significant differences between the IIM classifications, the associated SAD, the presence of cancer or ILD. However, longer follow-up periods and future studies are necessary to confirm these results.

Conclusion: The use of a myositis blot allowed classifying, stratifying the risk of ILD, the risk of cancer and the risk of mortality in IIM. IIM-ILD was the most frequent complication, usually manifested as NSIP. The associated risk factors were ILD, the risk of cancer and the risk of mortality in IIM. IIM-ILD was the most frequent manifestation (45.2% of the MSAs) in these patients. The main risk factors associated with IIM-ILD were some subtypes of the MSAs (p<0.001), the association of Ro52 (12.7%), Mi-2 (9.9%), PL-7 (9.9%), HMGCR (8.5%), PL-12 (7%), MDA-5 (5.6%) and SRP (5.6%) and EU (4.2%). The presence of Ro52 associated with other MSA was found in 20 patients (22.9%).

References:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.3248

POS0877 SARCOPIENIA IN MYOSITIS PATIENTS: A MARKER OF MUSCLE DAMAGE ASSOCIATED WITH HANDICAP


1Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland; 2Department of Biostatistics, at Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland; 3Department of Immune Modulators, University Hospital Zurich, Zurich, Switzerland; 4Department of Laboratory Medicine, University Hospital Zurich, Zurich, Switzerland; 5Department of Internal Medicine, University Hospital Zurich, Zurich, Switzerland; 6Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland; 7Department of Neurology, University Hospital Zurich, Zurich, Switzerland; 8Rheumatology Unit, Department of Medicine, University Hospital Zurich, Zurich, Switzerland.

Background: Sarcopenia is a systemic autoimmune rare diseases characterized by muscle inflammation and weakness. Even though the signs of active disease have been resolved, myositis patients frequently present residual muscle weakness, decreased physical performance and sustained disability. This condition has been coined on the term “damage” (as opposed to “activity”). Sarcopenia is a frequent, progressive and generalized muscle disorder characterized by low muscle strength and mass leading to handicap, decreased quality of life and increased mortality.

Prevalence and significance of sarcopenia in myositis patients has never been reported.

Objectives: To study sarcopenia in myositis patients with low or no disease activity.

Methods: Adult myositis patients (2017 ACR/EULAR criteria), with disease duration greater than 12 months, creatine kinase serum level (CK) less than 500 U/I, stable medication for 6 months were enrolled. Patients with inclusion body myositis were excluded. Total (LM) and appendicular (ALM) muscle mass were measured using dual-energy X-ray absorptiometry (DXA). Hologic and muscle grip strength was measured using Jamar dynamometer. Sarcopenia was defined according to the EWGSOP2 consensus.

Results: 29 patients (20 female, 68.9%), with a median age of 61 years (50.5-71) were enrolled. They suffered from dermatomyositis (DM, n=4), immune-mediated necrotizing myopathy (IMNM, n=8), anti-synthetase syndrome (ASS, n=9), scleromyositis (SM, n=8) since 4.7 years (2.8-8.3). At the evaluation, muscle strength assessed with MMT-8 was 139/150 (136-147), MMT-12 was 210/220 (204-216) and CK were 1315 U/I (1055-2024). Two patients (13.8%) were sarco- penic. Sarcopenic patients were older (73.4 years (66.2-80.5) vs 58.7 years (44.2-79.6), p=0.03), with a longer disease duration (7.3 years (5.3-11.8) vs 4.3 (2.7-3.8), p= 0.1), longer time with increased CK (449 days (169.8-954) vs 255.5 (124-872.6), higher maximum CK values (6000 U/I (2205-7000) vs 1636 (900-4451)). They suffered from JDM (2/4, 50%); DM (n=1) and SM (n=1), had more frequently disease-related cardiac involvement (50% vs 4%, p=0.04), and tended to a longer steroid therapy duration (2.4 years (0.8-5) vs 1.8 (1-3.9), p=0.9) and a higher number of immunomodulatory drugs (2.5 (2-5.3) vs 2 (2-3), p=0.3).

At the evaluation, sarcopenic patients were globally weaker as highlighted by lower MMT-12 (201 (196.8-206.8) vs 213 (207-217.5), p=0.02). Head flexo-extendors and proximal upper muscles were especially weaker (respectively, p=0.04 and p=0.03). Muscle performance was also lower in sarcopenic patients as assessed by distance covered at 6-minute walk test (6mWT, p=0.003) and number of squats in 30 seconds (p=0.005). Time to drink a glass of water was significantly longer in sarcopenics (p=0.04) even if any patient referred dysphagia. Health assessment questionnaire score was greater (1.4 (0.8-2) vs 0.6 (0-2.1), p=0.04) indicating higher handicap. Median grip strength was lower in sarcopenic patients (11.2 (5-19) vs 16 (7-23), p=0.02) as well as handgrip strength (11.2 (5-19) vs 16 (7-23), p=0.02) indicating higher handicap. LM positively correlated with MMT-8 (ρ=0.7, p=0.0003) and 6mWT distance covered/lower limit (p=0.04) indicating higher handicap. LM positively correlated with MMT-12 (ρ=-0.6, p=0.001) and 6mWT distance covered/lower limit (p=0.03) indicating higher handicap. LM positively correlated with time to drink a glass of water (ρ=0.6, p=0.002).

Conclusion: Muscle mass measured by DXA is a relevant parameter for muscle damage and disability in myositis patients. Sarcopenic myositis patients represent a subgroup with important muscle damage and handicap.

References:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.3248

POS0878 THE EFFECT OF PLATELET INHIBITORS ON DIGITAL ULCERS IN SYSTEMIC SCLEROSIS - A DERIVATION AND VALIDATION EUSTAR STUDY


1Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; 2Department of Biostatistics, at Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland; 3Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zürich, Switzerland; 4Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Sclerodema Unit, AUOC, Florence, Italy; 5Centre for Interdisciplinary Clinical Immunology, Rheumatology and Autoinflammatory Diseases and Department of Internal Medicine II (Hematology, Oncology and Immunology), University Hospital Tübingen, Germany; 6Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands; 7Department of Internal Medicine, Ghent University Hospital, Belgium; 8Department of Rheumatology, Ghent University Hospital, Belgium; 9Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Ghent, Belgium; 10Rheumatology Unit, Department of Medicine, University of Padova, Padova, Italy; 11Department of Rheumatology A. Descartes University, APHP Cochin Hospital, Paris, France; 12Unit of Immunology, Rheumatology,